Key result
Review assesses the evidence for P2Y12 inhibitor pretreatment before coronary angiography and PCI.
Why the study?
Recent trials did not fully resolve clinical questions surrounding pre-treatment timing, patient selection, and agent choice across available oral and intravenous P2Y12 inhibitors in ACS.
Does pre-treatment with P2Y12 inhibitors improve outcomes in patients with acute coronary syndrome planned for coronary angiography and possible PCI?
Does pre-treatment with P2Y12 inhibitors improve outcomes in patients with acute coronary syndrome planned for coronary angiography and possible PCI?
This review summarizes the evolving evidence on the optimal timing and choice of P2Y12 inhibitor pre-treatment in patients with acute coronary syndrome undergoing angiography.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“due to lack of evidence of benefit from studies such as ACCOAST, the very large SCAAR registry and ISAR-REACT 5. The pretreatment strategy is risky for some patients, including those requiring emergent bypass surgery, as well as for those with aortic dissection or undiscovered bleeding complications.”
May warrant individualized P2Y12 pre-treatment in ACS; leaves open optimal agent and timing from randomized evidence.
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12receptor inhibitor is the mainstay of treatment for acute coronary syndrome (ACS) patients, whether they undergo a percutaneous coronary intervention (PCI) or are managed medically. In recent years, the most appropriate timing for initiation and duration of P2Y12receptor inhibition has been a focus of great interest. Many observational studies and a single prospective trial (CREDO) utilizing clopidogrel had focused on whether pre-treatment with clopidogrel, i.e. its administration upstream of coronary angiography and PCI, is beneficial. Although the rationale for pre-treatment is obvious, large-scale randomized trials supporting a pre-treatment strategy with clopidogrel or with the newer P2Y12inhibitors prasugrel and ticagrelor did not exist. Proponents of a pre-treatment strategy had to rely on their best guess, on non-randomized studies, or on negative studies in which a trend for a benefit had been demonstrated. Recently, however, two randomized trials directly evaluated the value of pre-treatment-one in patients with a non-STE elevation myocardial infarction (NSTEMI)-the Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention or as Pretreatment at the Time of Diagnosis in Patients with Non-ST Elevation Myocardial Infarction (ACCOAST) trial, and a second trial evaluating the use of ticagrelor in ST-elevation myocardial infarction (STEMI) patients, the Administration of Ticagrelor in the Cath Lab or in the Ambulance for New ST-elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial. Neither of the two trials, however, answered all the questions clinicians have about pre-treatment. And given the recent approval of the intravenous and rapidly acting P2Y12inhibitor cangrelor, the choice of who should receive treatment with a P2Y12inhibitor, which one should be used, and when it should be administered, should be carefully re-evaluated for all patients. This clinical review aims at evaluating the available evidence regarding the value of pre-treatment with the now four available oral and intravenous P2Y12inhibitors that can be administered to patients in whom coronary angiography followed by a possible PCI is planned.
No takes yet. Share an insight, caveat, or question.
Sibbing et al. (2015) conducted a review in Acute coronary syndrome (ACS). Pre-treatment with P2Y12 inhibitors was evaluated. This clinical review evaluates the available evidence regarding pre-treatment with oral and intravenous P2Y12 inhibitors in patients planned for coronary angiography and possible PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: